For informational purposes only — not investment advice

← Back to signals

EVMN

Evommune, Inc.

Research: Finviz ↗·Perplexity ↗

No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.

Days to cover (short int.)
3.0d↑+17.1%
as of 2026-10-30 · shares short vs 2026-09-30

News Summary

Negative

Evommune expanded its pipeline via a $30M in-license of EVO570 (VAT1 degrader) from Hinova, funded by a $30M private placement at $6.04/share—78% below February pricing—signaling investor skepticism. Q3 results showed zero revenue, a $31M net loss (up 148% YoY), and 43% higher operating expenses, though the concurrent financing extended cash runway to H2 2029.

Red flags

  • •Revenue collapsed to zero in Q3 2026 from $10M in Q3 2025 (prior collaboration ended)
  • •Net losses more than doubled YoY to $31M despite no revenue generation
  • •Private placement priced 78% below prior raise in February 2026, indicating significant loss of investor confidence
  • •Operating expenses surged 43% YoY to $33M with no corresponding revenue; path to profitability unclear
  • •Analyst downgrade to 'strong sell' by Wall Street Zen (November 14, 2026) offset modest HC Wainwright estimate lift
  • •Early-stage pipeline (EVO301 Phase 2a, EVO570 newly in-licensed) carries high clinical and commercial risk with 2029 cash runway dependent on burn rate

Fund 13D/13G Filings (2)

Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).

FundForm∆ Shares% of ClassSince FilingFiledSrc
Point72SC 13G/A+524K6.7%
+5.2% vs SPY
+2.0% abs
2026-11-16↗
Point72SC 13GNEW5.3%
-53.5% vs SPY
-50.7% abs
2026-07-16↗